Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity

BACKGROUND: Doxorubicin is a widely used agent in the treatment of cancer, but the cardiotoxicity associated with this drug limits its potential for use. The cardioprotective effects of dapagliflozin, an antidiabetic drug, have the potential to counteract the cardiotoxic effect of doxorubicin therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulusan, Sebahat, Gülle, Kanat, Peynirci, Ahmet, Sevimli, Murat, Karaibrahimoğlu, Adnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Society of Cardiology 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250773/
https://www.ncbi.nlm.nih.gov/pubmed/37257007
http://dx.doi.org/10.14744/AnatolJCardiol.2023.2825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250773/
https://www.ncbi.nlm.nih.gov/pubmed/37257007
http://dx.doi.org/10.14744/AnatolJCardiol.2023.2825

Ejemplares similares